From the miRoncol archive: This historical update may contain promotional language or research findings that do not describe the current service. Retrospective research results do not establish prospective screening performance, and references to scientific prizes do not imply evaluation or endorsement of miRoncol or miCheckup. Do not rely on this archive for healthcare decisions; use the current product information and discuss screening decisions with a healthcare professional.
miRoncol was selected to present its microRNA research and development program at the New York Venture Summit in September 2024. The event connected investors, executives and emerging technology companies.
The 2024 Nobel Prize recognized the discovery of microRNA biology; it did not evaluate or endorse miRoncol, miCheckup or any product. Research-stage work presented at an investor event should not be read as established commercial performance or a guarantee of health outcomes.